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Abstract
In the present study, we demonstrated the suitability of liposomes as a method of removing plasma bilirubin in hyperbilirubinemic rats.
The liposomes have innate tendency to bind with bilirubin through hydrophobic interaction. Among different types of liposomes, the
positively charged liposomes were found to have maximum affinity to free bilirubin. However, the entrapment or coupling of serum albumin
on the surface of egg phosphatidylcholine liposomes can render a several-fold increase in their bilirubin binding capacity. The
proteoliposomes were able to preferentially bind with bilirubin even in the presence of erythrocytes. Interestingly, these liposomes were
found to displace bilirubin bound on the surface of erythrocytes as well. The results of the present study further demonstrate that albumin-
bearing liposomes were equally effective in removing plasma bilirubin in experimental jaundiced animals. These observations indicate that
liposome-mediated selective homing of excess plasma bilirubin to the liver cells (cf. hepatocytes) may help in the development of safer
strategy for the treatment of hyperbilirubinemic conditions in the model animals. D 2002 Elsevier Science B.V. All rights reserved.
Keywords: Bilirubin; Liposome; Jaundice; Albumin; Kernicterus; Reticuloendothelial system
1. Introduction
Bilirubin, a potentially toxic catabolic product of hae-
moglobin, is normally cleared from plasma after conjuga-
tion with glucuronic acid in the hepatocytes and finally
excreted into the bile [1,2]. Under normal physiological
conditions, plasma albumin interacts with bilirubin stoichio-
metrically and helps in its transportation to the liver [3,4].
However, in certain metabolic disorders such as jaundice or
in newborn infants with genetic deficiency or low levels of
bilirubin glucuronosyltransferase, the amount of unconju-
gated bilirubin (UB) in blood increases [2–4]. Besides, the
plasma UB level can also rise due to the overproduction of
the pigment in conditions such as hemolytic anemia [5]. The
elevated bilirubin level interferes with the normal function-
ing of the cellular machinery and eventually manifests
systemic toxicity [4,6]. Moreover, the high serum level of
the bilirubin when crossed the threshold level can contribute
to number of sequels specifically impairing cellular function
by blocking oxidative phosphorylation, inhibiting respira-
tion and finally resulting in fatal Kernicterus [1,4,7].
The interaction of bilirubin with lipid vesicles as well as
basolateral membranes has been studied extensively [8].
The liposomes are believed to bind with bilirubin involving
both ionic as well as hydrophobic interactions [8,9]. Fur-
ther, the liposomes can help in targeting of the bilirubin to
the liver and spleen, the two main components of the
reticuloendothelial system (RES), for its final removal from
the systemic circulation [10]. Keeping in view the high
affinity of bilirubin to lipids, we attempted to exploit the
liposomes (biodegradable lipid vesicles) for the removal of
bilirubin from systemic circulation of the jaundiced ani-
mals.
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Incidentally, bilirubin has high affinity for albumin as
well, thus entrapment or coupling of albumin onto the surface
of liposomes should result in several-fold increase in their
binding with bilirubin [11]. To test our hypothesis, we
evaluated various types of liposomes for their binding with
free as well as plasmamembrane-bound bilirubin. Finally, we
determined whether such liposomes would facilitate hepatic
uptake and vectorial transport of bilirubin. The in vivo studies
demonstrate that liposome-based bilirubin lowering formu-
lations will not only help in the formation of liposome–
bilirubin complex but also facilitate the clearance of bilirubin
from systemic circulation in the model animals.
2. Materials and methods
2.1. Materials
Egg phosphatidylcholine (egg PC) was isolated from egg
yolk and purified as described earlier [12]. Cholesterol
(Chol) was purchased from Centron Research laboratory,
Mumbai, India, and was used after crystallizing it three
times with methanol. Stearylamine (SA), phophatidylserine
(PS), gangliosides, sodium cyanoborohydride, fatty acid
free albumin (various animal sources) and bilirubin were
bought from Sigma. Sodium metaperiodate and ethylene-
diaminetetraacetic acid (EDTA) were obtained from Sisco
Research Laboratory, Mumbai, India. Sephadex G-75 and
Sepharose 6B were procured from Pharmacia Fine chem-
icals.
2.2. Methods
2.2.1. Preparation of bilirubin solution
Keeping into account the fact that contaminating impur-
ities present in the commercially supplied bilirubin might
interfere in liposome–bilirubin binding studies, it was
purified following the published procedure [13]. The recrys-
tallized bilirubin (about 5 mg) was dissolved in 1 ml of 38
mM sodium carbonate solution containing 1 mM EDTA (pH
11.0). This solution was centrifuged at 5000 rpm for 10 min
to remove insoluble bilirubin. The pH of the bilirubin
solution was adjusted to 8.0 with Tris buffer saline (10
mM Tris, 150 mM sodium chloride, pH 7.6). The concen-
tration of bilirubin was determined spectrophotometrically
using molar extinction coefficient 6.2 104 M 1 cm  1 at
453 nm. Bilirubin solution was protected from light to
prevent photodegradation and used within 30 min of its
preparation. All experiments were conducted with exclusion
of daylight, using light source covered with a double layer
of orange cellophane, transmitting very less illumination at
440 nm.
2.2.2. Preparation of liposomes
In the present study, the bilirubin was allowed to interact
with liposomes of different physicochemical properties. The
compositions of various types of the liposomes were as
follows:
Neutral liposomes: egg PC and Chol (7:3 molar ratio)
Negatively charged liposomes: egg PC, Chol and PS
(7:2:1 molar ratio)
Positively charged liposomes: egg PC, Chol and SA
(7:2:1 molar ratio)
Albumin coupled [human serum albumin (HSA)/OUT]
liposomes: egg PC, Chol and gangliosides
Albumin coupled/entrapped (HSA IN/OUT) liposomes:
egg PC, Chol and gangliosides (20:20:4 molar ratio)
Unilamellar lipid vesicles (ULVs) were prepared by
sonication method following published procedure as modi-
fied in our lab [14]. Briefly, the desired composition of the
lipids was dissolved in a chloroform–methanol mixture in a
thick glass tube, and the solvents were removed under a
slow jet of N2 to get a thin lipid film on the wall of the tube.
The traces of the solvents were removed by leaving the tube
overnight in vacuo. The film was dispersed in 0.8 ml of the
borate-buffered saline (10 mM borate, 60 mM NaCl, pH
8.4). The lipid dispersion was sonicated with probe soni-
cator for a total of 30 min (pulsed mode, 3 s pulse 2 s rest) at
4 jC under N2 atmosphere. The sonicated preparation was
centrifuged in RC5C cooling centrifuge at 10,000 rpm for 1
h at 4 jC to effect the removal of the titanium particles as
well as poorly dispersed lipid. Only the top two-thirds of the
supernatant was used in the further studies. The mean
diameter of these liposomes, as determined by negative
staining electron microscopy, was about 60F 10 nm.
2.2.3. Covalent coupling of serum albumin with liposomes
The entrapment of serum albumin in the liposomes was
effected by freeze–thaw method followed by coupling of
albumin onto the surface of liposomes [15]. The serum
albumins from various sources were covalently coupled to
the liposome surface as described earlier [16]. Briefly, the
liposomes were subjected to periodate oxidation for gener-
ating aldehyde group from gangliosides present on the
surface of liposomes. Subsequently, the vesicles were sep-
arated from the periodate on a 1.5 15-cm Sephadex G-75
column equilibrated in 20 mM borate, 120 mM NaCl (pH
8.4). The liposome peak was concentrated on an Amicon
centriflo cone (1500 rpm, 4 jC) using RC 3B cooling
centrifuge. For conjugation, oxidized liposomes (10 Amol
lipid in 1 ml) were mixed with 10 mg of given serum
albumin in 0.5 ml of 20 mM borate, 120 mM saline (pH
8.4). To the above mixture was added 15 Al of NaBH3CN (2
M) and the reaction mixture was left for 14 h at room
temperature. The uncoupled albumin was removed by
passing this mixture through 1.6 90 cm sepharose 6B
column, equilibrated with sucrose-supplemented Tris saline
(10 mM Tris, 44 mM sucrose, 120 mM NaCl and 5 mM
EDTA, pH 7.4) and albumin-coupled liposomes were eluted
in void volume. The peak corresponding to vesicles was
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concentrated using centriflo cone as described above. The
protein-to-lipid ratio in HSA/OUT liposomes was about 80
Ag/Amol of lipid Pi, while it was 96 Ag/Amol of lipid Pi for
HSA IN/OUT liposomes, as estimated by BCA reagent
method [17].
2.2.4. In vitro bilirubin binding to liposomes
The kinetics of bilirubin binding with liposomes was
determined by incubating various liposomal preparations
with bilirubin solution at 37 jC. The interaction was studied
in concentration- as well as time-dependent manner. Briefly,
liposomes (62.5–500 nmol lipid Pi/500 Al) were incubated
with 500 Al of 2:1 bilirubin/HSA mixture (total bilirubin
150 Amol) for 1 h at 37 jC in Tris buffer (10 mM Tris, 150
mM saline, pH 8.0). The unbound bilirubin was separated
on a 1.5 30-cm Sephadex G-75 column equilibrated in 10
mM Tris, 150 mM NaCl (pH 8.0). The liposomal peak was
concentrated on an Amicon centriflo cone (1500 rpm, 4 jC)
using RC 3B cooling centrifuge. We also determined
bilirubin binding with liposomes in the presence of isolated
erythrocytes as well as whole blood. Briefly, liposomes (250
nmol lipid Pi) were incubated with 2:1 bilirubin/HSA
mixture (total bilirubin 150 Amol) in the presence of human
erythrocytes (1108 cells) for 1 h at 37 jC, keeping final
volume of the reaction mixture 1 ml with Tris buffer saline.
The relative interaction of bilirubin with liposomes versus
erythrocyte surface was studied by incubating liposomes
with erythrocytes that were already saturated with bilirubin.
Briefly, bilirubin-saturated erythrocytes (1108 cells) were
incubated with various liposomal preparations (250 nmol
lipid Pi) for 1 h at 37 jC, keeping final volume 1 ml with
Tris buffer. The liposomes were separated by centrifugation
at 2000 rpm for 10 min at 4 jC and liposome-bound
bilirubin was estimated as described earlier [18]. Similarly,
the potential of erythrocytes to displace liposome-bound
bilirubin was studied by allowing them to interact with
bilirubin-saturated liposomes. Briefly, 250 nmol lipid Pi was
allowed to interact with erythrocytes (1108 cells) at 37
jC for 1 h. The erythrocytes and liposomes were separated
by centrifugation for 30 min at 2000 rpm at 4 jC using RC
3B centrifuge. Erythrocytes were further washed with TBS
by centrifugation at 2000 rpm for 10 min at 4 jC ( 3).
Both liposomes as well as erythrocytes were analyzed for
their bilirubin content following the published procedure
[19].
2.2.5. In vitro cytotoxicity assay of liposomes
The toxicity of different liposomal preparations was
measured by using the MTT—micro culture tetrazolium
assay using published procedure [20]. Briefly, human
embryonic kidney (HEK) cells at the exponential growth
phase were harvested and centrifuged at 2000 g for 5 min,
resuspended in complete medium. The cells were dispensed
in a 96-well plate (2 104 cells in 180 Al DMEM/well) and
incubated in a 5% humidified CO2 incubator at 37 jC. After
24 h, 20 Al liposomal solution was added in six replicates to
give final concentration of 0–2000 nM of liposomes (lipid
Pi) per milliliter. After 48 h of incubation at 37 jC, 20 Al/
well of MTT (stock solution 5 mg/ml PBS) was added and
the plate was again incubated for 4 h after which the
medium was removed by aspiration. DMSO (150 Al) was
added to each well and the formazan was dissolved by
gentle shaking. The plate was read immediately in a micro
plate reader (Ceres uv900c, Bio-Tech Instruments, USA)
operating at 540 nm. Wells with complete medium, lip-
osome and MTT, but without cells, were used as blanks.
Vincristine sulphate (40 nM) was able to induce 100%
killing of the cells and was used as positive control.
2.2.6. In vivo interaction of liposomes with plasma bilirubin
in jaundiced rats
Male albino Wistar rats were exposed with bilirubin/rat
serum albumin (RSA) (2:1 molar ratio) solution for three
alternate days to develop hyperbilirubinemic condition.
Each animal received 1 ml of bilirubin/RSA solution corre-
sponding to 75 AM bilirubin per dose; the first two doses
were administered by subcutaneous route, followed by last
intravenous injection of the same amount of bilirubin (75
AM in 1 ml isotonic buffer). The animals were divided in six
different groups; each consists of 10 animals.
1. Normal rats given no treatment
2. Hyperbilirubinemic rats given no liposomal treat-
ment
3. Hyperbilirubinemic rats given free RSA treatment
4. Hyperbilirubinemic rats given PC-liposomes treat-
ment
Fig. 1. Concentration-dependent binding of liposomes with bilirubin. The
effect of increasing amount (62.5–500 nmol lipid Pi) of liposomes on
binding with bilirubin was determined by incubating them with 2:1 HSA
and bilirubin (total bilirubin 150 AM) for 1 h at 37 jC, keeping final volume
1 ml in Tris buffer saline. Liposome-bound bilirubin was estimated
following published procedures as described in the Materials and methods
section. (o), Egg PC liposomes; (.), negatively charged liposomes; (z),
positively charged liposomes; (q), HSA (OUT) egg PC liposomes; (n),
HSA (IN/OUT) egg PC liposomes. Each value is the mean of three different
experimentsF S.D.
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5. Hyperbilirubinemic rats given RSA/OUT liposome
treatment
6. Hyperbilirubinemic rats given RSA IN/OUT lip-
osome treatment
The treatment of the hyperbilirubinemic rats with various
liposomal preparations was started the next day to the last
dose (i.v. injection) of bilirubin. Each animal was treated
with 250 nmol lipid Pi (0.4 ml buffer) corresponding to
various liposomal preparations daily through intravenous
route for four consecutive days. The serum level of bilirubin
as well as other liver functioning parameters were deter-
mined following published procedure [21]. Briefly, the
blood was collected by retro-orbital puncture on day 0 (6
h after the last dose of liposome treatment), day 3 and day 9
post-liposomal treatment and analyzed for its bilirubin as
well as other enzyme contents.
2.2.7. Statistical analysis
The effect of proteoliposome treatment on the plasma
bilirubin level of hyperbilirubinemic animals was tested by
the Student’s t-test. A P value of less than < 0.05 was
considered statistically significant.
Fig. 3. Binding of bilirubin with erythrocytes in the presence of lipid
vesicles. Human erythrocytes (1108 cells) were incubated with 2:1 HSA
and bilirubin (total bilirubin 150 AM) in the presence of different liposomal
preparations (250 nmol lipid Pi) for 1 h at 37 jC. The mixture was
centrifuged to separate erythrocytes from liposomes and unbound bilirubin.
The erythrocyte-bound bilirubin was estimated following published
procedures as described in the Materials and methods section. The values
shown represent mean of five different experimentsF S.D.
Fig. 2. Time-dependent binding of bilirubin to various liposomal
preparations. Unilamellar liposomes (625 nmol lipid Pi) were incubated
with 2:1 HSA and bilirubin (total bilirubin 150 AM) for different time
intervals at 37 jC in TBS solution. The liposome-bound bilirubin was
estimated following published procedures as described in the Materials and
methods section. (o), Egg PC liposomes; (.), negatively charged
liposomes; (z), positively charged liposomes; (q), HSA (OUT) egg PC
liposomes; (n), HSA (IN/OUT) egg PC liposomes. Each value is the mean of
three separate experimentsF S.D.
Table 1
Relative affinity of liposomised serum albumin with erythrocyte-bound
bilirubin
Liposomes Percentage eluted
bilirubin
Rat serum albumin 42.66F 1.38
Human serum albumin 89.33F 0.94
Pig serum albumin 97.33F 1.4
Human erythrocyte (1108) cells were incubated with 150 AM bilirubin/
HSA solution in TBS as described earlier for 1 h at 37 jC. The unbound
bilirubin was removed by washing erythrocytes extensively with TBS. The
bilirubin-bound erythrocytes were allowed to incubate with albumin-
bearing liposomes for 1 h at 37 jC. The bilirubin transferred to liposomes
was determined as described earlier. The spontaneous leaching of bilirubin
from untreated erythrocytes was less than 1%. The values shown are mean
of three different experimentsF S.D.
Fig. 4. Relative affinity of bilirubin with erythrocyte versus liposomes.
Human erythrocytes (1108 cells) were incubated with 2:1 HSA and
bilirubin (total bilirubin 150 AM) for 1 h at 37 jC. The unbound bilirubin
was removed by extensive washing with TBS. The erythrocytes were then
incubated with different liposomal formulations for 1 h at 37 jC. The
mixture was centrifuged at 2000 rpm to separate erythrocytes. Liposome-
bound bilirubin was estimated by analyzing supernatant for its bilirubin
content following published procedures as described in the Materials and
methods section. The spontaneous leaching of bilirubin from erythrocytes
(no liposome treatment) was less than 1%. The data shown express mean of
five separate experimentsF S.D.
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3. Results
The bilirubin was found to interact with various lip-
osomal preparations in concentration- as well as time-
dependent manner (Figs. 1 and 2). The composition of the
liposomes seems to play an important role in such inter-
actions. Among various types of liposomes, the positively
charged liposomes were shown to have higher bilirubin
binding as compared to the neutral liposomes. Negatively
charged liposomes did not interact substantially with bilir-
ubin at any concentration. However, the bilirubin binding
capacity of the neutral liposomes increased significantly
when serum albumin (HSA) was either entrapped inside
or covalently coupled onto the surface of liposomes (Figs. 1
and 2). The binding of the bilirubin with albumin-bearing
liposomes depends on the source of the albumin and differs
from species to species. Among different kinds of albumins,
the rat albumin was found to bind the least while porcine
albumin has the maximum bilirubin binding capacity (Table
1).
We have also demonstrated that the presence of ery-
throcytes did not affect the bilirubin binding capacity of
albumin-coupled liposomes (Fig. 3). The results of the
present study suggest that bilirubin, when present in excess,
can interact with both erythrocytes as well as neutral lip-
osomes with equal propensity, that is, the presence of
liposomes or erythrocyte in the same reaction mixture did
not affect their binding with bilirubin substantially. On the
other hand, the presence of negatively charged liposomes
did not affect the binding of bilirubin with erythrocytes (Fig.
3). The positively charged liposomes behaved differently;
they were adsorbed onto the surface of erythrocyte (personal
observation) resulting in overall increase in binding of
bilirubin with erythrocyte (Figs. 3 and 4). Further, we also
studied the relative binding of bilirubin to erythrocytes in
the presence of liposomes. Our results show that erythro-
cyte-bound bilirubin can be easily knocked out by both
HSA/OUT as well as HSA IN/OUT liposomes (Fig. 4). On
the contrary, erythrocytes were not effective in the displace-
ment of proteoliposome-bound bilirubin (Fig. 5). In other
words, proteoliposomes bind bilirubin much better as com-
pared to erythrocytes under these conditions.
The toxicity of different liposomal preparations was ruled
out by incubating cells with liposomes for different time
periods. The killing of the cells was considered as parameter
for assessing the safety of liposomes. Results shown in
Table 2 clearly demonstrate that liposomes are safe at the
dose of 2 AM Pi/ml.
Finally, various liposomal preparations were evaluated for
their potential to eliminate plasma bilirubin from systemic
circulation in model animals. Our preliminary experiments
demonstrated that the single dose therapy (250 nmol lipid Pi)
was not much effective in the elimination of plasma bilirubin
from systemic circulation of the model animals. For example,
the RSA IN/OUT liposomes were able to remove only 35–
40% of the excess bilirubin present in the hyperbilirubinemic
rats (data not shown). Moreover, it was followed by recur-
rence in the plasma bilirubin level and suggested that single
dose therapy would not be successful in the treatment of
hyperbilirubinemic conditions. We tried several dosage regi-
mens and found that the schedule followed in the present
study was most successful in normalizing the plasma bilir-
ubin level in the hyperbilirubinemic rats.
Fig. 5. Transfer of liposome-bound bilirubin to human erythrocytes. Lipo-
somes (250 nmol lipid Pi) were preincubated with 2:1 HSA and bilirubin
(total bilirubin 150 AM) for 1 h at 37 jC, keeping final volume 1 ml with
TBS. The unbound bilirubin was removed and bilirubin-containing
liposomes were then incubated with erythrocytes for 1 h at 37 jC. After a
stipulated time period, the erythrocytes were separated from the above
mixture by centrifugation. The bilirubin transferred to the erythrocytes/
retained by liposomes was estimated following published procedure as
described in the Materials and methods section. The data shown in the figure
are representative of five different experiments.
Table 2
Cytotoxic effect of different liposomal preparations on HEK cells
Dose Percentage cell survival
(nmol Pi/ml)
Neutral
liposomes
Negatively
charged
liposomes
Positively
charged
liposomes
HSA/OUT
liposomes
0 98.5F 0.8 98.0F 1.0 99.2F 1.11 99.6F 0.6
125 98.8F 0.6 98.4F 0.6 97.2F 0.6 98.4F 1.2
250 97.2F 0.5 97.2F 0.8 96.2F 0.4 97.8F 0.8
500 96.2F 1.1 96.2F 1.2 95.5F 0.9 96.2F 0.4
1000 96.0F 1.2 96.4F 0.6 93.0F 0.8 96.6F 0.6
2000 96.4F 0.5 96.4F 0.8 92.2F 0.8 96.0F 0.2
The HEK cells were dispensed in a 96-well plate as described in Materials
and methods section. The cells were treated with increasing doses (in six
replicates) of 0–2000 nmol of liposomes (lipid Pi) per milliliter. After 48 h
of incubation at 37 jC, MTT was added and formazan was dissolved by
gentle shaking. The plate was read immediately in a micro plate reader
(Ceres uv900c) operating at 540 nm. Wells with complete medium,
liposome and MTT, but without cells, were used as blanks. Vincristine
sulphate (40 nM) was able to induce 100% killing of the cells and was used
as positive control. The percentage toxicity was determined by calculating
cells surviving in the test wells as compared to the liposome-untreated HEK
cells. The data represent means of six different observationsF S.D.
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Among different liposomal formulations tested on day 0,
the egg PC liposomes eliminated around f 28% of the
excess bilirubin, while RSA/OUT liposomes were effective
in removal of the f 55% of the excess bilirubin when
compared with the untreated animals. The level of plasma
bilirubin was finally reduced to 1.13 and 0.76 mg/dl in egg
PC liposome (P < 0.001) and RSA OUT (P < 0.001) lip-
osome-treated animals, respectively, when determined on
day 9 post-treatment. The RSA IN/OUT liposomes were
found to be most effective as these successfully normalized
the plasma bilirubin concentrations within 6 h (day 0) post-
treatment (P < 0.001). Interestingly, there was no recurrence
in plasma bilirubin level in RSA IN/OUT treated animals
even on day 9 post-treatment. Besides, these liposomes were
also successful in normalizing the other liver functioning
enzyme levels as well (Table 3). There was no substantial
reduction in plasma bilirubin level of the animals (control
group) treated with free albumin even on day 9 post-treat-
ment (data not shown).
4. Discussion
We have recently demonstrated that bilirubin has
domain-specific binding sites on serum albumin [22,23].
In fact, the normal serum level of bilirubin is maintained by
its specific binding with albumin that poses significant
physiological repercussions in terms of bilirubin toxicity
[1,4,6]. The bilirubin–albumin complex, when reaches to
the liver, is specifically recognized by certain factors, the
putative albumin receptors of the hepatocytes, which induce
conformational changes in the albumin molecules to facil-
itate the release of bilirubin for subsequent degradation in
the liver cells [24]. However, the bilirubin detoxifying
function of the liver cells cannot cope well under conditions
when plasma bilirubin exceeds its normal level [1,3,4]. The
excess bilirubin remains in the systemic circulation for
longer duration and exerts its cytotoxic effect to different
tissues including brain cells [1,4,7].
It is widely believed that UB, a lipophilic compound, has
an intrinsic affinity for lipids (cf. phospholipid) of biological
membranes and other lipid structures such as vesicles and
micelles [8,9]. In concordance with the earlier reports, the
results of the present study confirm that liposome can interact
with free bilirubin in time- and concentration-dependent
manner (Figs. 1 and 2). Moreover, we observed that the size
as well as lamellarity of the liposomes was not contributing
much in binding with bilirubin (data not shown). However,
the surface charge of the liposomes was crucial in bilirubin–
liposomes interaction. The higher bilirubin binding to the
positively charged liposomes indicated the involvement of
electrostatic interactions in the binding process. In other
words, it appears that among the three species of bilirubin,
both bilirubin di-anion as well as mono-anion have prefer-
ences over bilirubin acid to bind with liposomes. The higher
binding of the bilirubin with positively charged liposomes
could be explained on the premise that apart from hydro-
phobic interactions, the anionic species of bilirubin should
have an extra edge in binding with positively charged lip-
osomes through ionic interactions as well.
Our study that involves interaction of bilirubin with
liposomes in the presence of blood components implicates
that bilirubin-bound positively charged liposomes have a
tendency to undergo adsorption onto the surface of the
erythrocytes (personal observation). This interaction can
be attributed to the respective charges present on two
Table 3
Liver functioning test of the bilirubin-exposed rats after treatment with different liposomal preparations
Group Determination
of liver
functioning test
Alkaline
phosphatase
(IU/l)
SGOT (IU/l) SGPT (IU/l) Bilirubin (mg/dl)
Normal Day 0 8.14F 0.74 15.5F 0.41 9.5F 0.41 0.53F 0.05
Day 3 8.26F 0.90 16.0F 0.90 9.8F 0.85 0.56F 0.05
Day 9 8.10F 0.40 16.2F 0.78 9.7F 0.80 0.51F 0.04
Untreated Day 0 28.2F 0.85 34.13F 0.70 20.2F 0.58 1.84F 0.08
Day 3 29.4F 0.60 35.0F 1.10 19.8F 0.90 1.85F 0.08
Day 9 28.8F 0.52 35.2F 1.1 20.0F 0.80 1.89F 0.09 *
Egg PC Day 0 20.8F 0.19 20.4F 1.1 15.5F 0.41 1.30F 0.047
liposomes Day 3 20.0F 0.08 17.4F 0.80 15.2F 0.84 1.20F 0.09
Day 9 19.8F 0.07 17.0F 0.60 15.0F 0.60 1.13F 0.09 *
RSA/OUT Day 0 11.2F 0.49 16.8F 0.71 10.8F 0.24 0.84F 0.09
liposomes Day 3 10.6F 0.38 16.0F 0.28 10.3F 0.24 0.80F 0.07
Day 9 10.0F 0.34 15.8F 0.46 10.0F 0.30 0.76F 0.05 *
RSA IN/OUT Day 0 9.4F 0.80 15.1F 0.18 9.9F 0.12 0.56F 0.04
liposomes Day 3 9.2F 0.60 15.3F 0.28 9.8F 0.20 0.54F 0.02
Day 9 8.4F 0.40 15.4F 0.45 9.6F 0.80 0.53F 0.02 *
The male albino Wistar rats (n= 10 for each group) were injected with bilirubin and RSA (2:1 ratio, total bilirubin 75 AM) in TBS as described in Materials and
methods section. The hyperbilirubinemic animals were then treated with various liposomal preparations. The bilirubin level was determined after different time
interval post-liposome treatment. The table shows level of different liver functioning parameters in 10 animals from each group. The animals were randomly
bled before the treatment and the LFTwas determined following published procedures. The data shown are mean of the values from 10 different animalsF S.E.
* P < 0.001.
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interacting moieties. Thus, the use of positively charged
liposomes may have detrimental effects on erythrocytes, and
might not be the right strategy for its future use in the
treatment of hyperbilirubinemia. The observed binding
behavior of positively charged liposomes with bilirubin in
the presence of erythrocytes or whole blood led us to tailor
the neutral egg PC liposomes for increasing their bilirubin
binding capacity.
Keeping into consideration the higher affinity of albumin
with bilirubin, we speculated that its entrapment in the
aqueous core compartment, or coupling onto the outer
surface of liposomes would enhance its binding with bilir-
ubin several folds to that of the free albumin. The results of
the present study clearly show the increased binding
capacity of albumin-bearing liposomes with bilirubin (Figs.
1 and 2). The bilirubin–proteoliposome interaction was not
affected by the presence of erythrocytes (Fig. 3). These
liposomes not only possess higher binding to the free
bilirubin but also have the potential to dislodge plasma
membrane-bound bilirubin from the living cells as well (Fig.
4). It seems that such liposomes have the ability to bind with
the free bilirubin through lipid moiety as well as albumin
residues present on the surface.
For most of the in vitro experiments, we used HSA as
model albumin with the idea that results of such studies can
have direct correlation with their possible future use in the
human subjects. However, we preferred to use RSA-bearing
liposomes for in vivo studies performed in the Wistar rats.
Nevertheless, RSA more closely mimics the physical prop-
erties of human albumin, at least with regard to bilirubin
binding properties among different serum albumins [25].
Moreover, use of HSA was likely to exert some allogenic
immunological responses in rats.
Our in vivo results suggest that proteoliposomes can
offer an alternate approach to treat the hyperbilirubinemic
conditions (Table 3). The liposome-based therapy should
certainly find wide application, especially in the situations
when hyperbilirubinemic conditions are induced by differ-
ent pathological conditions or reduced albumin binding in
sick or premature infants [26]. Similarly, jaundice induced
by glucose-6-phosphate dehydrogenase deficiency with
concurrent infection could also be successfully treated with
albumin-bearing liposomes [27]. However, this approach
would find limited scope in conditions when hyperbilirubi-
nemic condition is inflicted by impairment of bilirubin
glucuronosyl transferase, an enzyme responsible for glucur-
onidation of bilirubin before its final excretion in the bile
[2–4].
Since liposomes are avidly taken up by the RES (liver
and spleen), one can argue that liposome-based treatment
can redirect bilirubin to its site of origin. This can be
explained on the premise that after reaching the liver, the
liposomes will have equal access to both kupffer cells as
well as hepatocytes [28]. Besides, the presence of albumin
receptors as well as bilirubin carrier molecules (bilitranslo-
case) on the surface of hepatocytes can facilitate the uptake
of bilirubin-bearing liposomes [4,23,27]. Further, the pro-
teoliposome can provide temporary sink to the bilirubin thus
minimizing the risk of bilirubin toxicity. In fact, liposome-
mediated uptake of bilirubin could be more advantageous in
the sense that single molecule of the bilirubin upon inter-
action with its carrier present in the plasma membrane of the
hepatocyte can carry several other molecules present in the
single liposome.
The earlier methods for removing bilirubin from the
plasma include use of resins or charcoals [29,30]. The resin
columns are likely to induce hypokalemia/hypocalcemia-
like situations by binding to the essential ions of the plasma
[31], while charcoal has limitation in being minimally
effective, as well as suffer with other blood compatibilities
such as generation of particulate emboli [32]. Besides, most
of these methods are prone to extracorporeal blood clotting
and need use of excessive anticoagulants for hemoperfusion
[33]. Similarly, phototherapy used for the treatment of
jaundiced infants has its own limitations as the optimal
dose of light is not yet clear and shorter wavelength light
(350–450 nm) may be mutagenic [34,35].
Since higher plasma bilirubin level usually results from
the liver disorders mainly [1–3,36], the liposomes can be
proved of multipurpose importance as we can load them
with the drugs having liver-correcting functions. Finally, we
conclude that liposome-based therapy can have advantage
over other cumbersome methods such as hemoperfusion or
photooxidation where hospitalization as well as presence of
medical staff become essential for the treatment and special
arrangements have to be made for passing the blood through
columns containing bilirubin-binding resins.
Acknowledgements
We are thankful to the Co-ordinator Prof. M. Sale-
emuddin for providing the facilities to complete this work.
M.A.K. and S.M.F. are thankful to the UGC as well as CST
(Government of India), respectively, for the financial
assistance.
References
[1] W.B. Karp, Pediatrics 64 (1979) 361–366.
[2] F. Vanstapel, N. Blanckaert, N. Tavoloni, P.D. Berk, Hepatic transport
and bile secretion, Physiology and Pathophysiology, Raven Press,
New York, 1993, pp. 477–488.
[3] S.C. Hauser, J.C. Ziurys, J.L. Gollan, Gastroenterology 91 (1986)
287–296.
[4] G.R. Gourley, Adv. Pediatr. 44 (1997) 173–229.
[5] W.H. Schwesinger, W.E. Kurtin, J. Surg. Res. 35 (1983) 520–524.
[6] S. Schenker, A.M. Hoyumpa, D.W. McCandless, Bilirubin toxicity to
brain (kernicterus) and other tissues, in: J.D. Ostrow (Ed.), Bile Pig-
ments and Jaundice, Marcel Dekker, New York, 1986, pp. 395–415.
[7] T.W.R. Hansen, D. Bratlid, Acta Paediatr. Scand. 75 (1986) 513–522.
[8] E.F. Erikson, D. Henning, R. Broderson, J. Biol. Chem. 256 (1981)
4269–4274.
A.K. Masood et al. / Biochimica et Biophysica Acta 1564 (2002) 219–226 225
[9] M.G. Mustafa, T.E. King, J. Biol. Chem. 245 (1970) 1084–1089.
[10] M.J. Hsu, R.L. Juliano, Biochim. Biophys. Acta 720 (1982) 411–419.
[11] R. Broderson, J. Biol. Chem. 254 (1979) 2364–2369.
[12] W.S. Singleton, M.S. Gray, M.L. Brown, J. Am. Oil Chem. Soc. 42
(1965) 53–56.
[13] A.F. McDonagh, F. Assisi, Biochem. J. 129 (1972) 797–800.
[14] M. Owais, C.M. Gupta, Eur. J. Biochem. 267 (2000) 3946–3956.
[15] M. Owais, G.C. Varshney, A. Chaudhury, S. Chandra, C.M. Gupta,
Antimicrob. Agents Chemother. 39 (1995) 180–184.
[16] T.D. Heath, B.A. Macher, D. Papahadjopoulos, Biochim. Biophys.
Acta 640 (1981) 66–81.
[17] P.K. Smith, R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner,
M.D. Provenzano, E.K. Fujimoto, N.M. Goeke, B.J. Oslon, D.C.
Klenk, Anal. Biochem. 150 (1985) 76.
[18] J. Fog, Scand. J. Clin. Lab. Invest. 10 (1958) 241–245.
[19] S. Tayyab, M.K. Ali, J. Biochem. Biophys. Methods 39 (1999) 39–45.
[20] D.A. Scudiero, R.H. Shoemaker, K.D. Paull, A. Monks, S. Tierney,
H. Nofziger, M.J. Currens, D. Seniff, M.R. Boyd, Cancer Res. 48
(1988) 4827–4833.
[21] M.A. Jafri, J.M. Subhani, K. Javed, S. Singh, J. Ethnopharmacol. 66
(1999) 355–361.
[22] M.M. Khan, S. Tayyab, Biochim. Biophys. Acta 36356 (2000) 1–15.
[23] S. Tayyab, N. Sharma, M.M. Khan, Biochem. Biophys. Res. Com-
mun. 277 (2000) 83–88.
[24] R.G. Reed, C.M. Burrington, J. Biol. Chem. 264 (17) (1989) 9867–
9872.
[25] S.D. Zucker, W. Goessling, J.L. Gollan, J. Biol. Chem. 270 (1995)
1074–1081.
[26] H.D. Arkans, G. Cassady, J. Paediatr. 92 (1978) 1001–1005.
[27] E. Beutler, Blood 84 (1994) 3613–3636.
[28] D.K. Meijer, P. Vander Sluijs, Pharm. Res. 6 (2) (1989) 105–108.
[29] S. Sideman, L. Mor, J.M. Brandes, Trans. Am. Soc. Artif. Intern.
Organs 25 (1979) 497–500.
[30] T.S. Lie, W.I. Kim, A. Holst, U. Grunn, K. Rommenshein, Acta
Hepato-Gastroenterol. 23 (1976) 262.
[31] J.L. Rosenbaum, G. Onesti, C. Heider, J. Am. Med. Assoc. 180 (1962)
762–764.
[32] T.M.S. Chang, A. Gonda, J.F. Dirks, T. Lee-Burns, Trans. Am. Soc.
Artif. Intern. Organs 18 (1972) 465–467.
[33] Y. Idezuki, M. Hamaguchi, S. Hamabe, H. Moriya, T. Nagashima, H.
Watanabe, T. Sonoda, K. Teramoto, T. Kikuchi, H. Tanzawa, Trans.
Am. Soc. Artif. Intern. Organs 27 (1981) 428–430.
[34] J.F. Ennever, Clin. Perinatol. 17 (1990) 467–481.
[35] S. Onishi, S. Itoh, K. Isobe, Biochem. J. 236 (1986) 23–25.
[36] J. Gollon, R. Schmid, R. Wright, G.H. Millward-Sadler, K.G.M.M.
Albertii, S. Karran (Eds.), Liver and Biliary Disease, 2nd edn., Bail-
lere-Tindall, London, 1985, pp. 301–357.
A.K. Masood et al. / Biochimica et Biophysica Acta 1564 (2002) 219–226226
